Abstrait

N2-3 stage nasopharyngeal carcinoma patients with cervical node necrosis and extracapsular spread benefit from capecitabine maintenance chemotherapy.

Ting Liu , Siwen Liu, Yuting Gu, Xuehua Wen

The purpose of this study was to analyze the efficacy and toxicities of concurrent chemoradiotherapy plus capecitabine maintenance chemotherapy for N2-3 stage Nasopharyngeal Carcinoma (NPC) with Cervical Node Necrosis (CNN) and Extra Capsular Spread (ECS). Patients and methods: This study included 283 N2-3 stage NPC patients with CNN and Extra Capsular Spread who were treated with concurrent chemoradiotherapy. The prescribed doses delivered to the Planning Target Volumes (PTVs), PTVnx, PTVnd, PTV1, and PTV2, were 68- 72, 66-70, 60-64, and 52-56 Gy, respectively, in 30-32 fractions. All patients received induction chemotherapy followed by concurrent chemoradiotherapy with cisplatin alone (80-100 mg/m2, Day 1, every 21 days is a cycle). Two weeks after completion of concurrent chemoradiotherapy, oral capecitabine (twice daily after meals for 14 consecutive days every 3 weeks) was administered to maintenance chemotherapy patients. Maintenance chemotherapy was administered for 6 months.